Search

Shyr J Li

from Millbrae, CA
Age ~64
Get Report
Also known as:
Shyr Jiann Li, Shyr Chia Li, Jiann Li Shyr, Shyrjiann Jiann Li, Shyrjiann L Li, Li J Shyr, Li Shyrjiann
Phone and address:
1388 Broadway UNIT 458, Millbrae, CA 94030
(510) 579-6710
Related to:
Laura T Li, 85Xiaolan Li, 50Hao LiYan Liu, 53Liefang Li, 67
Connected to:
Ai Q Li, 63Ai H Li, 80Aida Li, 67Aijun Li, 65Aiwen Q Li, 56Aiyan Li, 61Alan Li, 80Alice Li, 46Alida Li, 58Alisha Li, 30

Shyr Li Phones & Addresses

  • 1388 Broadway UNIT 458, Millbrae, CA 94030 (510) 579-6710
  • Redwood City, CA
  • 849 Orange Ave, Ssf, CA 94080 (650) 624-9118
  • South San Francisco, CA
  • Naperville, IL
  • 169 School St, Hamden, CT 06518
  • Chicago, IL
  • San Francisco, CA
  • Fremont, CA
  • 1388 Broadway UNIT 458, Millbrae, CA 94030

Publications

Us Patents

Bruton's Tyrosinie Kinase Activity Probe And Method Of Using

View page
US Patent:
20130225812, Aug 29, 2013
Filed:
Apr 3, 2013
Appl. No.:
13/856380
Inventors:
Shyr Jiann Li - San Francisco CA, US
Heleen Scheerens - Menlo Park CA, US
Lee Honigberg - San Francisco CA, US
Erik Verner - Belmont CA, US
Assignee:
Pharmacyclics, Inc. - Sunnyvale CA
International Classification:
C07D 487/04
US Classification:
544262
Abstract:
Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.

Bruton's Tyrosine Kinase Activity Probe And Method Of Using

View page
US Patent:
20080214501, Sep 4, 2008
Filed:
Nov 5, 2007
Appl. No.:
11/935277
Inventors:
Zhengying PAN - Alpharetta GA, US
Shyr Jiann Li - South San Francisco CA, US
Heleen SCHEERENS - Menlo Park CA, US
Lee HONIGBERG - San Francisco CA, US
Erik VERNER - Belmont CA, US
Assignee:
PHARMACYCLICS, INC. - Sunnyvale CA
International Classification:
A61K 31/69
C07F 5/02
C12N 9/12
US Classification:
514 64, 544229, 435194
Abstract:
Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.

Parvovirus Antibodies For Veterinary Use

View page
US Patent:
20220267414, Aug 25, 2022
Filed:
Jul 30, 2020
Appl. No.:
17/630685
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Ellen Ratcliff - Burlingame CA, US
Richard Chin - San Francisco CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C07K 16/08
A61P 31/20
Abstract:
Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus.

Il4/Il13 Receptor Molecule For Veterinary Use

View page
US Patent:
20210395340, Dec 23, 2021
Filed:
Oct 24, 2019
Appl. No.:
17/287756
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Fawn Qian - Burlingame CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C07K 14/715
A61K 38/17
A61K 45/06
G01N 33/68
Abstract:
Provided are various embodiments relating to IL13R/IL4R heterodimeric proteins derived from companion animal species and that bind to IL13 and/or IL4. Such heterodimeric proteins can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.

Fc Variants With Altered Binding To Neonatal Fc Receptor (Fcrn) For Veterinary Use

View page
US Patent:
20210388053, Dec 16, 2021
Filed:
Oct 18, 2019
Appl. No.:
17/284875
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Qingyi Chu - Burlingame CA, US
Richard Chin - San Francisco CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C07K 14/705
Abstract:
Provided are various embodiments relating to variant IgG Fc polypeptides with altered FcRn binding activity. Also provided are polypeptides and pharmaceutical compositions comprising the variant IgG Fc polypeptides described herein. Polypeptides comprising variant IgG Fc polypeptides of the present invention may have extended half-life in vivo. Such products may be used in methods to treat disease in companion animals, such as canines, felines, and equines.

Variant Asparaginase Polypeptides For Medical Use

View page
US Patent:
20210062176, Mar 4, 2021
Filed:
Apr 18, 2019
Appl. No.:
17/048355
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Richard Chin - San Francisco CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C12N 9/82
A61P 35/00
Abstract:
Provided are various embodiments relating to variant asparaginase polypeptides with enhanced stability, pharmacodynamics, and/or reduced immunogenicity. The variant asparaginase polypeptides may be used as therapeutics in mammals, including human, canines, felines, and equines.

Erythropoietin And Analogs For Veterinary Use

View page
US Patent:
20210032305, Feb 4, 2021
Filed:
Jun 5, 2018
Appl. No.:
16/617380
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Yongzhong Li - Burlingame CA, US
Qingyi Chu - Burlingame CA, US
Estela Garcia-Murillo - Burlingame CA, US
Victoria Leitman - Burlingame CA, US
Stephen Sundlof - Burlingame CA, US
Richard Chin - San Francisco CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C07K 14/505
A61K 47/60
A61K 47/26
Abstract:
Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Igg Fc Variants For Veterinary Use

View page
US Patent:
20200362034, Nov 19, 2020
Filed:
Aug 15, 2018
Appl. No.:
16/638402
Inventors:
- Burlingame CA, US
Lam Nguyen - Union City CA, US
Yongzhong Li - Rockville MD, US
Fawn Qian - Burlingame CA, US
Shyr Jiann Li - Millbrae CA, US
Assignee:
Kindred Biosciences, Inc. - Burlingame CA
International Classification:
C07K 16/28
C07K 14/605
A61K 9/00
A61P 3/04
Abstract:
Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction, increased stability, and/or the ability to form heterodimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. Also provided are various embodiments relating to contiguous polypeptides comprising one or more variant GLP1 polypeptide(s) having improved serum half-life. Further provided are various embodiments relating to contiguous polypeptides or heterodimeric polypeptides comprising a GLP1 polypeptide and a glucagon polypeptide as a dual GLP1 receptor and glucagon receptor agonist. In various embodiments, such polypeptides may be used to treat, for example, diabetes, obesity, or related indications, in companion animals, such as canines, felines, and equines.
Control profile
Shyr J Li from Millbrae, CA, age ~64 Get Report